![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
| Item Type: | Dataset |
|---|---|
| Title: | Towards a proteomic plasma biomarker panel for diagnosing vasculitis remission |
| Creators: |
Kirchner, Marieluise  ORCID: https://orcid.org/0000-0002-7049-534X and Mertins, Philipp ORCID: https://orcid.org/0000-0002-2245-528X
|
| Abstract: | Active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) requires intensive immunosuppressive therapy, but continued treatment after remission is achieved can cause serious harm. Reliable biomarkers to confirm remission are lacking, forcing clinicians to prolong cost-intensive and toxic therapy unnecessarily. Routine markers, such as C-reactive protein and anti-neutrophil cytoplasmic antibodies, lack sensitivity and specificity for the remission status, failing to guide treatment de-escalation safely. After adjusting for patient characteristics and clinical variables, we explored the plasma proteome to identify reliable biomarkers of disease remission in patients with AAV. We applied a two-tiered proteomics strategy combining global discovery with targeted validation to identify a protein signature of remission. The resulting 7-protein panel was successfully implemented in a targeted mass spectrometry-based assay, with diagnostic performance confirmed in an independent patient cohort. The panel consistently outperformed routine markers. Our findings suggest that this panel may serve as a starting point for developing a clinical tool to support decision-making, with the potential to reduce treatment-related burden, mitigate toxicity, and lower healthcare costs. Moreover, our confounder-controlled proteomics approach provides a scalable blueprint for biomarker discovery in complex inflammatory diseases. |
| Source: | PRIDE |
| Publisher: | EMBL-EBI |
| Date: | 5 June 2026 |
| External Fulltext: | View full text on external repository or document server |
| Related to: |
Repository Staff Only: item control page
